Adverse Drug Reactions (Postmarketing)

The incidence of adverse events observed in lenvatinib monotherapy datasets for reactions identified from postmarketing use of lenvatinib are provided in Table 10.

Table 10: Incidence of Adverse Events Reported for Lenvatinib in Monotherapy Datasets for Reactions Identified from Postmarketing Use of Lenvatinib
MedDRA Preferred Terms
/ CTCAE
Lenvatinib DTC   Monotherapy N=458 Lenvatinib RCC   Monotherapy N=52 Lenvatinib HCC   Monotherapy N=496 All Lenvatinib Monotherapy   (1)  N=1823
Any Grade Grade ≥3 Any Grade Grade ≥3 Any Grade Grade ≥3 Any Grade Grade ≥3
Cholecystitis / cholecystitis acute 1.5 1.1 3.8 3.8 0.6 0.4 1.6 1.1
Pancreatitis / pancreatitis acute 0.7 0.7 0 0 0.2 0.2 0.7 0.5
Lipase increased / Hyperlipasemia 3.7 2.6 11.5 7.7 3.6 2.6 3.4 2.1
Amylase increased / Hyperamylasemia 2.4 1.5 3.8 3.8 1 0.4 1.7 0.9
Aortic Dissection 0 0 0 0 0.2 0.2 0.1 0.1
Impaired healing 1.3 0.2 0 0 0.2 0.2 0.8 0.2
Pneumothorax 1.3 0.7 0 0 0.4 0.2 0.9 0.4
Nephrotic syndrome 0.2 0 0 0 0 0 0.2 0
Osteonecrosis of the jaw 0.2 0 0 0 0 0 0.1 0
1 Includes studies of lenvatinib as a monotherapy in subjects with other types of cancer.

Disclaimer

This website is intended for healthcare professionals only. To proceed, please indicate your PRC (Professional Regulation Commission) number for verification purposes.

By clicking "Continue," you consent to the collection and use of your PRC number and any other personal data provided for the purpose of confirming your professional credentials and accessing restricted content in this site. Your data will be handled in accordance with our Data Privacy Policy and applicable data protection laws.

If you do not consent to these terms, please exit the site.

Oops! We could not locate your form.